Get the Stockscreener App
2.56
1.19%
0.03
After Hours:
2.54
-0.02
-0.78%
Lipocine Inc stock is traded at $2.56, with a volume of 232.79K.
It is up +1.19% in the last 24 hours and down -65.12% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.53
Open:
$2.51
24h Volume:
232.79K
Relative Volume:
0.63
Market Cap:
$18.69M
Revenue:
$1.98M
Net Income/Loss:
$-9.63M
P/E Ratio:
-1.4502
EPS:
-1.7653
Net Cash Flow:
$-9.76M
1W Performance:
+20.19%
1M Performance:
-65.12%
6M Performance:
-17.69%
1Y Performance:
-16.07%
1-Day Range:
$2.48
$2.63
1-Week Range:
$2.01
$2.63
52-Week Range:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.56 | 18.47M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
LPCN stock crashes 78%—here’s why - MSN
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Quarterly Risk: What is the Moat Score of Lipocine IncMarket Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
What's going on with Lipocine stock on Monday? - MSN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 - Investing.com UK
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 By Investing.com - Investing.com India
Director John Higuchi adds 40,000 Lipocine (LPCN) shares at $2.03 - Stock Titan
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock - Defense World
CEO Mahesh Patel Increases Stake in Lipocine Inc with Recent Sha - GuruFocus
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 By Investing.com - Investing.com Australia
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Director John W. Higuchi buys 123K Lipocine (LPCN) shares at $2.05 - Stock Titan
Lipocine CEO Patel acquires $50,749 in LPCN stock - Investing.com UK
Lipocine CEO Patel acquires $50,749 in LPCN stock By Investing.com - Investing.com India
Lipocine (LPCN) CEO adds 25,000 shares in stock purchase - Stock Titan
Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - biocentury.com
LPCN Downgraded to Neutral by HC Wainwright & Co. | LPCN Stock N - GuruFocus
What's Going On With Lipocine Stock On Monday? - Benzinga
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
H.C. Wainwright Downgrades Lipocine(LPCN.US) to Hold Rating - Moomoo
Lipocine Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
Lipocine Faces Market Setback as LPCN 1154 Fails Key Trial - StocksToTrade
LPCN Should I Buy - Intellectia AI
Lipocine Stock Plummets After Clinical Trial Disappointment - StocksToTrade
Lipocine Updates Investor Presentation to Refine Market Messaging - The Globe and Mail
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Lipocine Inc (ticker: LPCN) announced that its experimental drug for postpartum depression failed to meet the primary endpoint in its Phase III clinical trial, causing the company's stock price to plummet by 78.4% in pre-market trading. - Bitget
Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget
LPCN | Lipocine Inc. Insider Trading - Quiver Quantitative
CEO Mahesh Patel Acquires 25,000 Shares of Lipocine Inc (LPCN) - GuruFocus
Lipocine CEO buys 25,000 shares in open market | LPCN Insider Trading - Stock Titan
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld MedTech
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
Lipocine weighs path after LPCN 1154 Phase 3 miss - TipRanks
Lipocine Reports Topline Safety and Efficacy Results for LPCN 11 - GuruFocus
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Lipocine stock tumbles after phase 3 trial misses endpoint By Investing.com - Investing.com Australia
Lipocine stock tumbles after phase 3 trial misses endpoint - Investing.com
Lipocine's postpartum depression pill misses main goal in late-stage study - TradingView — Track All Markets
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):